Acute Effects of the Human Amylin Analog AC137 on Basal and Insulin-Stimulated Euglycemic and Hypoglycemic Fuel Metabolism in Patients with Insulin-Dependent Diabetes Mellitus

Journal of Clinical Endocrinology and Metabolism

Volumn 81, Issue 3, 1996, Pages 1083-1089

  Nyholm, Birgit ^a   Møller, Niels ^a   Gravholt, Claus H ^a   Ørskov, Lotte ^b   Mengel, Annette ^b   Bryan, Gillian ^c   Moyses, Chris ^c   Alberti, K George M M ^d   Schmitz, Ole ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b AARHUS UNIVERSITY   (Denmark)

^c Amylin Europe Ltd   (United Kingdom)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

RODENTIA;

AMYLIN; AMYLIN DERIVATIVE; INSULIN; PLACEBO; PRAMLINTIDE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERINSULINEMIA; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN METABOLISM; LACTATE BLOOD LEVEL; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AMYLOID; DIABETES MELLITUS, TYPE 1; ENERGY METABOLISM; FOREARM; GLUCOSE; HORMONES; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; MALE; REFERENCE VALUES; REGIONAL BLOOD FLOW; TIME FACTORS;

EID: 0029867855     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jcem.81.3.8772580     Document Type: Article

References (47)

1. Hartter E, Svoboda T, Ludvik B, et al. 1991 Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with insulin in humans. Diabetologia. 34:52-54.
2. Mitsukawa T, Takemura J, Asai J, et al. 1990 Islet amyloid polypeptide response to glucose, insulin, and somatostatin analogue administration. Diabetes. 39:639-642.
3. Johnson KH, O'Brien TD, Betsholtz C, Westermark P. 1989 Islet amyloid, islet-amyloid polypeptide, and diabetes mellitus. N Engl J Med. 321:513-518.
4. Clark A, Saad MF, Nezzer T, et al. 1990 Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia. 33:285-289.
5. Cooper GJS, Willis AC Clark A, Turner RC, Sim RB, Reid KBM. 1987 Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA. 84:8628-8632.
6. Cooper GJ, Leighton B, Dimitriadis GD, et al. 1988 Amylin found in amyloid deposits in human type 2 diabetes mellitus may be a hormone that regulates glycogen metabolism in skeletal muscle. Proc Natl Acad Sci USA. 85:7763-7766.
7. Leighton B, Cooper GJS. 1990 The role of amylin in the insulin resistance of non-insulin-dependent diabetes mellitus. TIBS. 15:295-299.
8. Permert J, Larsson J, Westermark GT, et al. 1994 Islet amyloid polypeptide in patients with pancreatic cancer and diabetes. N Engl J Med. 330:313-318.
9. Young DA, Deems RO, Deacon RW, Mcintosh H, Foley JE. 1990 Effects of amylin on glucose metabolism and glycogenolysis in vivo and in vitro. Am J Physiol 259:E457-E461.
10. Leighton B, Cooper GJS. 1988 Pancreatic amylin and calcitonin gene-related peptide causes resistance to insulin in skeletal muscle in vitro. Nature. 355: 632-635.
11. Young AA, Gedulin B, Wolfe-Lopez D, Greene HE, Rink T, Cooper GJS. 1992 Amylin and insulin in rat soleus muscle: dose responses for cosecreted non-competitive antagonists. Am J Physiol 263:E274-E281.
12. Gedulin B, Cooper GJS, Young AA. 1991 Amylin secretion from the perfused pancreas: dissociation from insulin and abnormal elevation in insulin-resistant diabetic rats. Biochem Biophys Res. 180:782-789.
13. Young AA, Cooper GJS, Carlo P, Rink T, Wang MW. 1993 Response to intravenous injection of amylin and glucagon in fasted, fed, and hypoglycemic rats. Am J Physiol 264:E943-950.
14. Frontoni S, Choi SB, Banduch D, Rossetti L. 1991 In vivo insulin resistance induced by amylin primary through inhibition of insulin-stimulated glycogen synthesis in skeletal muscle. Diabetes. 40:568-573.
15. Sowa R, Sanke T, Hirayama J, et al. 1990 Islet amyloid polypeptide amide causes peripheral insulin resistance in dogs. Diabetologia. 33:118-120.
16. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Bloom S. 1990 Failure to establish islet amyloid polypeptide (amylin) as a circulating beta cell inhibiting hormone in man. Diabetologia. 33:115-117.
17. Bretherton-Watt D, Gilby SG, Ghatei MA, Baecham J, Macrae AD, Bloom S. 1992 Very high concentrations of islet amyloid polypeptide are necessary to alter the insulin response to intravenous glucose in man. J Clin Endocrinol Metab. 74:1032-1035.
18. Wilding JPH, Khandan-Nia N, Bennet WM, et al. 1994 Lack of acute effect of amylin (islet associated polypeptide) on insulin sensitivity during hyperinsulinemic euglycaemic clamp in humans. Diabetologia. 37:166-169.
19. Blackard WG, Clore JN, Kellum JM. 1994 Amylin/insulin secretory ratios in morbidly obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol Metab. 78:1257-1260.
20. Lehman De Gaeta LS, Willis AC, Young AA, et al. 1991 Variability of chemical synthesized human amylin [Abstract]. Diabetes. 40(Suppl 1):236A.
21. Hartter E, Svoboda T, Lell B, et al. 1990 Reduced islet-amyloid polypeptide in insulin-dependent diabetes mellitus. Lancet. 335:854-855.
22. Koda JK, Fineman M, Rink TJ, Dailey GE, Muchmore DB, Linarelli LG. 1992 Amylin concentration and glucose control. Lancet. 339:1179-1180.
23. Akimoto K, Nakazato M, Matsukura S, Hayakawa K. 1993 Plasma concentration of islet amyloid polypeptide in healthy children and patients with insulin-dependent diabetes mellitus. Acta Pediatr. 82:310-311.
24. Diabetes Control and Complication Trial Research Group. 1993 The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 329:977-986.
25. Moyses C, Kolterman O, Nuttall A, Mant T. 1994 First administration to man of the human amylin analogue tripro-amylin [Abstract]. Diabetologia. 43(Suppl 1):A72.
26. Frayn KN. 1983 Calculation of substrate oxidation rates in vivo from gaseous exchange. J Appl Physiol. 55:628-634.
27. Whitney RJ. 1953 The measurement of volume changes in human limbs. J Physiol (Lond). 121:1-27.
28. Forster CD, Taylor JY, Macdonald IA. 1991 Monitoring molecules in neuroscience: the assay of the catecholamine content of small volumes of human plasma. In: Rollema H, Westerlink BHC, Drijshout WJ, eds. Gronningen: University of Gronningen; 173-175.
29. Ørskov H, Thomsen HG, Yde H. 1968 Wick-chromatography for rapid and reliable immunoassay of insulin, glucagon and growth hormone. Nature. 219:193-197.
30. Harrison J, Hodson AV, Skillen AW, Stappenbeck R, Agius L, Alberti KGMM. 1988 Blood glucose, lactate, pyruvate, glycerol, 3-hydroxyburyrate and acetoacetate measurements in man using a centrifugal analyser with a flourimetric attachment. J Clin Chem Clin Biochem. 26:141-146.
31. Percy AJ, Trainor D, Rittenhouse J, Janes SM, Koda JE. 1994 Sensitive two-site enzyme immunoassays for amylin and amylin-like peptides in human plasma [Abstract]. Diabetologia. 37(Suppl 1):A117.
32. 14C-glucose. Recent Prog Horm Res. 19:445-488.
33. Kautzky-Wilier A, Thomaseth K, Pacini G, et al. 1994 Role of islet polypeptide secretion in insulin-resistant humans. Diabetologia. 37:188-194.
34. Macintyre I. 1989 Amylinamide, bone conservation, and pancreatic β cell. Lancet. 2:1026-1027.
35. Kassir AA, Upadhyay AK, Lim TJ, Moossa AR, Olefsky JM. 1991 Lack of effect of islet amyloid polypeptide in causing insulin resistance in conscious dogs during euglycemic clamp studies. Diabetes. 40:998-1004.
36. Hwang JH, Pershegin G, Rotman DL, et al. 1995 Impaired net hepatic glucogen synthesis in insulin-dependent diabetic subjects during mixed meal ingestion. J Clin Invest. 95:783-787.
37. Ørskov L, Alberti KGMM, Mengel A, et al. 1991 Decreased hepatic glucagon responses in type 1 (insulin-dependent) diabetes mellitus. Diabetologia. 34: 521-526.
38. Young AA, Wang MW, Cooper GJS. 1991 Amylin injection causes elevated plasma lactate and glucose in the rat. FEBS Lett. 291:101-104.
39. Young AA, Gedulin B, Gaeta LSL, et al. 1994 Selective amylin antagonist suppresses rise in plasma lactate after intravenous glucose in rat. FEBS Lett. 343:237-241.
40. Abildgaard N, Ørskov L, Petersen JAK, Alberti KGMM, Schmitz O, Møller N. 1995 Forearm substrate exchange during hyperinsulinemic hypoglycemia in normal man. Diabetic Med. 12:218-223.
41. Suzuki S, Murakami M, Abe S, et al. 1992 The effect of amylin on insulin secretion from RIN m5F cells and glycogen synthesis and lipogenesis in rat primary cultured hepatocytes. Diabetes Res Clin Pract. 15:77-84.
42. Degano P, Silvestre RA, Salas M, Peiro E, Marco J. 1993 Amylin inhibits glucose induced insulin secretion in a dose-dependent manner. Regul Pept. 43:91-96.
43. Fürsinn C, Leuvenink H, Roden M, et al. 1994 Islet amyloid polypeptid inhibits insulin secretion in conscious rats. Am J Physiol. 267:E300-E305.
44. Cryer PE, Fisher JN, Shamon H. 1994 Hypoglycemia. Diabetes Care. 17:734-755.
45. Gerich J, Langlois M, Noacco C, Karam J, Forsham P. 1973 Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic α-cell defect. Science. 182:171-173.
46. Bolli G, De Feo P, Compagnucci P, et al. 1983 Abnormal glucose counter-regulation in insulin-dependent diabetes mellitus: interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes. 32: 134-141.
47. Cryer PE. 1994 Hypoglycemia: the limiting factor in the management of IDDM. Diabetes. 43:1378-1389.